PDUFA III Authorizes FDA To Alert Doctors Of Failed Phase IV Commitments
This article was originally published in The Tan Sheet
Executive Summary
FDA will have the authority to require that manufacturers inform doctors of a failure to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
You may also be interested in...
Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill
Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets
PDUFA III Could Move Through Congress In 2001, Rep. Burr Suggests
FDA's post-approval surveillance system should be discussed as part of the reauthorization process for the Prescription Drug User Fee Act, Rep. Richard Burr (R-N.C.) said during a May 3 House Energy & Commerce Committee/Health Subcommittee hearing on implementation of the FDA Modernization Act.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC